Previous 10 | Next 10 |
Harmony Biosciences Holdings (NASDAQ:HRMY), Aquestive Therapeutics (NASDAQ:AQST), C4 Therapeutics (NASDAQ:CCCC), Century Therapeutics (NASDAQ:IPSC), COMPASS Pathways (NASDAQ:CMPS) have been added to the Nasdaq Biotechnology Index. All the additions will be effective prior to market ...
WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced its inclusion ...
C4 Therapeutics (NASDAQ:CCCC): Q3 GAAP EPS of -$0.51 beats by $0.08. Revenue of $8.5M (+0.6% Y/Y) beats by $0.69M. Press Release For further details see: C4 Therapeutics EPS beats by $0.08, beats on revenue
– Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63 rd ASH Annual Meeting – – Investigational New Drug (IND) Application for CFT8634, a Degrader ...
Do You Have These Top Biotech Stocks On Your Radar Today? With the global pandemic raging on, biotech stocks have and continue to take center stage in the stock market today. This would be the case since Pfizer’s ( NYSE: PFE ) and BioNTech’s ( NASDAQ:...
– Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expected in 2022 – – Received Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma – – Initia...
WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the U.S. ...
C4 Therapeutics (CCCC) announces the closing of an underwritten public offering of 4.89M shares at a price of $37/share for aggregate gross proceeds of $180.8M.The offering included the exercise in full by the underwriters of their option to purchase up to an additional 637.5K share...
WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the closing of...
– CFT7455 Demonstrated High Binding Affinity to Cereblon and Target Selectivity in Non-Hodgkin’s Lymphoma Cell Models, Producing Rapid and Deep Degradation of IKZF1/3 Proteins – – CFT7455 Resulted in Improved Efficacy and Potency in Tumor Xenograft Mo...
News, Short Squeeze, Breakout and More Instantly...
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that preliminary data from the monotherapy dose escalation portion of the ongoing...
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the UBS Targeted Prote...
Cooper Brings Decades of Global Pharmaceutical and Biotechnology Leadership Experience Bruce Downey Remains a Member of the Board of Directors and Chair of the Organization, Leadership and Compensation Committee Transition Further Highlights Commitment to Strategically Transform t...